title: [Rivaroxaban: Xarelto--recommendations for pharmacists].
abstract: Rivaroxaban is one of the new oral anticoagulants (NOACs). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.
authors: Département de pharmacie, Université de Namur, Namur.
authors: J
authors: J
authors: Douxfils
authors: S
authors: S
authors: Michel
authors: C
authors: C
authors: Beauloye
authors: M
authors: M
authors: Goethals
authors: P
authors: P
authors: Hainaut
authors: H
authors: H
authors: Heidbuchel
authors: C
authors: C
authors: Hermans
authors: B
authors: B
authors: Ickx
authors: K
authors: K
authors: Jochmans
authors: S
authors: S
authors: Mottes
authors: F
authors: F
authors: Mullier
authors: A
authors: A
authors: Peeters
authors: C
authors: C
authors: Scavée
authors: P
authors: P
authors: Sinnaeve
authors: M
authors: M
authors: Sprynger
authors: V
authors: V
authors: Thijs
authors: C
authors: C
authors: Vandenbroeck
authors: E
authors: E
authors: Vandermeulen
authors: P
authors: P
authors: Verhamme
authors: J M
authors: JM
authors: Dogné
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010595:Pharmacists; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D009025:Morpholines; D013876:Thiophenes; D014812:Vitamin K; D000069552:Rivaroxaban